“Studied in humans” covers a very wide range of evidence. A small first exploration, a large controlled trial and years of systematic follow-up answer different questions. The phrase becomes misleading when the design and sample size disappear from the summary.
The 1996 melanotan II pilot involved three male volunteers. It explored early physiological and pigmentation observations under a research design. That is evidence that researchers observed effects in those participants, not a demonstration of an acceptable benefit-risk balance for widespread cosmetic use.
With so few participants, one person's experience can strongly affect the apparent pattern. The sample cannot represent the range of ages, health conditions, skin characteristics and concurrent medicines in a broader population. It also provides little opportunity to detect uncommon harms.
Early-phase research often helps investigators decide what questions to pursue next. That developmental purpose differs from proving a treatment is ready for routine use. A proposed future research exposure in an old paper is not a prescribing recommendation and should not be extracted into an internet protocol.
The comparator and masking arrangements also deserve attention. They help interpret what was observed, but they do not overcome the fundamental scale limitation. Calling a study controlled does not make every conclusion equally secure; precision, follow-up and applicability still need assessment.
Likewise, a visible effect is not the entire clinical outcome. Pigment change does not establish prevention of skin cancer, satisfaction across users or a safe relationship with UV exposure. Symptoms observed during a pilot should not be reframed as either proof of quality or a complete catalogue of possible harms.
For a reader, the useful practice is to ask what the study could reasonably detect. Three participants can generate hypotheses and demonstrate an initial observation. They cannot close long-term safety questions or validate a product sold decades later by another supplier.
This article does not reproduce administration details. The point is to recognize the difference between historical research and an evidence base sufficient for a clinical recommendation. Keeping the small sample visible is essential to an honest description of what is known.